Cabozantinib (thyroid cancer) Uses, Dosage, Side Effects and Interactions
Cometriq
Cometriq was the first cabozantinib (thyroid cancer) product the FDA approved, in November 2012.
Cabometyx
Cabometyx came 3 years after Cometriq (April 2016) as a tablet, a form not listed for Cometriq.
Cabozantinib (sold as Cabometyx tablets) is a kinase inhibitor, a targeted cancer medicine used for advanced kidney cancer, liver cancer, differentiated thyroid cancer and certain neuroendocrine tumors.
Quick links
Ask Anything About Cabozantinib (thyroid cancer)Type a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Cabozantinib (thyroid cancer) in Short
- Drug class Kinase Inhibitor How the FDA classifies it
What it treatsCabometyx tablets treat several cancers. The main ones are advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), differentiated thyroid cancer and neuroendocrine tumors.
- How you get it Prescription only
- Crushing or chewingSome forms are on our Do Not Crush list Listed: Cabometyx (tablet); Cabozantinib malate (capsule; tablet); and 1 more
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
The Pharmacist’s Take
Cabozantinib (Cabometyx), on the U.S. market since about 2012, is a targeted cancer medicine that blocks MET, VEGFR and RET, proteins tumors use to grow, spread and build blood vessels. For differentiated thyroid cancer it is a later option, used when radioactive iodine is not an option and an earlier VEGFR-targeted drug has stopped working, and it also treats kidney cancer, liver cancer and neuroendocrine tumors. Side effects are common, mainly diarrhea, tiredness, poor appetite and sore, red palms and soles, and doses are often lowered to keep it manageable. Watch above all for bleeding, and call right away for coughing up blood, vomiting blood or black stools.
Key Takeaways From the HelloPharmacist Team
- Take it once a day on an empty stomach, at least 1 hour before or 2 hours after food, swallowed whole.
- Expect regular blood pressure checks and urine protein, thyroid and calcium tests, since it can raise blood pressure and strain the heart.
- Start treating diarrhea at the first loose stool and report it if severe or persistent, since a dose pause or reduction often helps.
- Avoid grapefruit and St. John’s wort, and have your pharmacist check every new medicine, since many change cabozantinib levels.
Cabozantinib (thyroid cancer) by the Numbers
- Earliest FDA record
- 2012
- Rank by Medicaid prescriptions
- #1,121 of 1,682 drugs
- More prescriptions than 33% of the 1,682 drugs we measure
- 3,853 prescriptions, Q1–Q4 2025
Patient Information Guide for Cabozantinib (thyroid cancer)
What It’s Used For
Cabometyx tablets are approved for several cancers:
- Advanced renal cell carcinoma (kidney cancer), and as first treatment together with nivolumab
- Hepatocellular carcinoma (liver cancer) previously treated with sorafenib
- Differentiated thyroid cancer in adults and children 12 and older, locally advanced or metastatic, that progressed after VEGFR-targeted therapy and is radioactive iodine-refractory or ineligible
- Previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in adults and children 12 and older
How It Works
Cabozantinib blocks the activity of several tyrosine kinases, which are proteins that send growth signals. These include MET, VEGFR-1, -2 and -3, AXL and RET, among others. These proteins are involved in tumor growth, spread, blood vessel formation and drug resistance. Blocking them helps slow the cancer.
Drug Class
Drug Class
- Kinase Inhibitor
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Kinase Inhibitor
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Protein Kinase Inhibitors
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Cabozantinib (thyroid cancer) in the FDA’s index.
From our Patient Information GuideCabozantinib blocks the activity of several tyrosine kinases, which are proteins that send growth signals. These include MET, VEGFR-1, -2 and -3, AXL and RET, among others. Read How Cabozantinib (thyroid cancer) Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Cabozantinib (thyroid cancer) in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Other protein kinase inhibitors
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Cabometyx is a tablet taken by mouth once daily. Your prescriber sets the dose based on your condition, weight, liver function and other medicines.
- Take it on an empty stomach, at least 1 hour before or 2 hours after eating.
- Swallow tablets whole. Do not crush, chew or split them.
- Do not take a missed dose within 12 hours of the next one.
- Do not swap tablets for cabozantinib capsules.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Advanced kidney cancer
Adults Usual dose 60 mg once a day
- 60 mg orally once daily until disease progression or unacceptable toxicity
Adults taking it with nivolumab Usual dose 40 mg once a day
Step by step
- 40 mg orally once daily in combination with 240 mg nivolumab every 2 weeks (30-minute intravenous infusion)
- -OR- 480 mg nivolumab every 4 weeks (30-minute intravenous infusion)
- -OR- 600 mg nivolumab and 10,000 units hyaluronidase subcutaneously over approximately 3-5 minutes every 2 weeks
- -OR- 1,200 mg nivolumab and 20,000 units hyaluronidase subcutaneously over approximately 3-5 minutes every 4 weeks
- Cabometyx until disease progression or unacceptable toxicity
- Nivolumab (or nivolumab and hyaluronidase) until disease progression or unacceptable toxicity for up to 2 years
Liver cancer
For adults previously treated with sorafenib
Usual dose 60 mg once a day
- 60 mg orally once daily until disease progression or unacceptable toxicity
Thyroid cancer or neuroendocrine tumors
Adults and children 12 years and older weighing 40 kg or more Usual dose 60 mg once a day
- 60 mg orally once daily until disease progression or unacceptable toxicity
Children 12 years and older weighing less than 40 kg Usual dose 40 mg once a day
- 40 mg orally once daily until disease progression or unacceptable toxicity
Good to Know for Every Dose
Take on an empty stomach, at least 1 hour before or at least 2 hours after eating
Side Effects
Common side effects include:
Common side effects
- Diarrhea
- Tiredness (fatigue)
- Hand-foot skin reaction (redness, pain on palms and soles)
- Decreased appetite
- High blood pressure
- Nausea and vomiting
- Weight loss
- Constipation
When to get medical help
- Call your doctor right away for any bleeding, such as coughing up blood, vomiting blood or black stools. Cabometyx can cause severe and fatal bleeding.
- Seek help for severe belly pain, fever or signs of infection. Tears in the gut (perforation) and abnormal connections (fistulas) can occur.
- Get emergency help for chest pain, sudden shortness of breath, leg swelling or stroke symptoms. Blood clots and heart attacks can occur.
- Tell your doctor if your blood pressure is very high or you have a severe headache. Hypertensive crisis is possible.
- Report seizures, severe headache, vision changes or confusion. These can signal reversible posterior leukoencephalopathy syndrome (RPLS), a brain swelling condition.
- Report jaw pain, toothache, gum sores or slow healing after dental work. Osteonecrosis of the jaw can occur.
- Tell your doctor about severe or persistent diarrhea, or signs of heart failure.
- Report symptoms of low calcium or underactive thyroid, such as tiredness.
Warnings and Precautions
- Severe and fatal bleeding can occur. It should not be used with a recent history of bleeding.
- Gut perforations and fistulas can occur.
- Blood clots, including heart attack, can occur.
- High blood pressure and hypertensive crisis can occur.
- Heart failure can occur.
- Severe diarrhea, hand-foot skin reaction and protein in the urine can occur.
- Jaw bone damage and poor wound healing can occur, so stop it at least 3 weeks before surgery.
- Thyroid problems and low calcium can occur.
- It can cause fetal harm.
Interactions
Some medicines and foods change cabozantinib levels.
- Strong CYP3A4 inhibitors raise levels and the risk of side effects.
- Strong or moderate CYP3A4 inducers lower levels and may reduce effectiveness.
- Grapefruit and grapefruit juice may raise levels.
- St. John’s wort may lower levels.
Interactions Listed in the FDA-Approved Label
From the Cabozantinib (thyroid cancer) prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Strong CYP3A4 inhibitorsWhat happensCoadministration of a cabozantinib capsule formulation with a strong CYP3A4 inhibitor increased cabozantinib exposure, which may increase the risk of exposure-related adverse reactions.What to doAvoid coadministration; reduce the CABOMETYX daily dose by 20 mg if it cannot be avoided, and resume the prior dose 2 to 3 days after the inhibitor is stopped.
-
Grapefruit or grapefruit juiceWhat happensMay also increase exposure of cabozantinib.What to doAvoid grapefruit or grapefruit juice.
-
Strong or moderate CYP3A4 inducersWhat happensCoadministration of a cabozantinib capsule formulation with a strong CYP3A4 inducer decreased cabozantinib exposure, which may reduce efficacy.What to doAvoid coadministration; if it cannot be avoided, increase the daily CABOMETYX dose by 20 mg as tolerated, do not exceed 80 mg daily, and resume the prior dose 2 to 3 days after the inducer is stopped.
-
St. John's wortWhat happensMay also decrease exposure of cabozantinib.What to doAvoid St. John's wort.
Read the label’s full interactions text
7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Reduce the CABOMETYX dosage if coadministration cannot be avoided. Strong or moderate CYP3A4 inducers: Increase the CABOMETYX dosage if coadministration cannot be avoided. 7.1 Effects of Other Drugs on CABOMETYX Strong CYP3A4 Inhibitors Coadministration of a cabozantinib capsule formulation with a strong CYP3A4 inhibitor increased the exposure of cabozantinib, which may increase the risk of exposure-related adverse reactions. Avoid coadministration of CABOMETYX with strong CYP3A4 inhibitors. Reduce the dosage of CABOMETYX if coadministration with strong CYP3A4 inhibitors cannot be avoided. Avoid grapefruit or grapefruit juice which may also increase exposure of cabozantinib. Strong or Moderate CYP3A Inducers Coadministration of a cabozantinib capsule formulation with a strong CYP3A4 inducer decreased the exposure of cabozantinib, which may reduce efficacy. Avoid coadministration of CABOMETYX with strong or moderate CYP3A4 inducers. Increase the dosage of CABOMETYX if coadministration with strong or moderate CYP3A4 inducers cannot be avoided. Avoid St. John’s wort which may also decrease exposure of cabozantinib.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Recent bleeding history
- Uncontrolled high blood pressure
- Moderate liver impairment (dose reduced); severe impairment (avoid)
- Planned surgery or dental procedures
- Pregnancy: can harm the baby; use effective birth control during treatment and for 4 months after
- Breastfeeding: not advised during treatment and for 4 months after
- Children 12 and older: growth monitoring is needed if growth plates are open
- Mild or moderate kidney impairment: no dose change needed; no experience in severe kidney impairment
- Older adults: no overall differences in safety or effectiveness
Overdose
One reported overdose involved a patient who took twice the intended dose for 9 days. The patient had serious memory problems, mental status changes and cognitive disturbance, plus weight loss. Contact your doctor or poison control right away if you take too much.
Half-Life and How Your Body Processes It
Peak levels occur about 3 to 4 hours after a dose. Levels build up with daily dosing, reaching steady state by about day 15. A high-fat meal raised levels in a capsule study, which is why the tablet is taken on an empty stomach. The half-life is about 99 hours. It is mostly broken down by the CYP3A4 enzyme and cleared mainly in feces, with some in urine.
Storage
Store CABOMETYX at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Cabozantinib (thyroid cancer): Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Cabozantinib (thyroid cancer) — the kind of thing our pharmacy team would talk through with you at the counter.
What is Cabometyx used for?
How do I take Cabometyx?
What happens if I miss a dose of Cabometyx?
What side effects should I expect?
Can I have grapefruit or take St. John’s wort with Cabometyx?
Is Cabometyx safe in pregnancy?
Is cabozantinib (thyroid cancer) available over the counter?
When was cabozantinib (thyroid cancer) first available?
What is the brand name of cabozantinib (thyroid cancer)?
What is the generic name of Cometriq?
What drug class is cabozantinib (thyroid cancer)?
Is there a cabozantinib (thyroid cancer) shortage?
Where can I read the cabozantinib (thyroid cancer) prescribing information (package insert)?
Can you crush cabozantinib (thyroid cancer)?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Cabozantinib (thyroid cancer)
Skip the scrolling. Ask in your own words and get an answer from Cabozantinib (thyroid cancer)’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Cabozantinib (thyroid cancer)’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Cabozantinib (thyroid cancer) on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Cabozantinib (thyroid cancer) on the U.S. Market: Products, Makers and Brands
How Cabozantinib (thyroid cancer) appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
The FDA lists Cabozantinib (thyroid cancer) products; the earliest marketing or approval year on record is 2012.
How Widely Cabozantinib (thyroid cancer) Is Used (Medicaid Data)
How many Cabozantinib (thyroid cancer) prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Cabozantinib (thyroid cancer) prescribed? Of the 1,682 medications we measure, Cabozantinib (thyroid cancer) ranks #1,121 by Medicaid prescriptions — more than 33% of them.
Utilization by Cabozantinib (thyroid cancer) product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
cabozantinib 40 MG Oral Tablet Most dispensed
1 of 4 listed NDCs had Medicaid claims. RxNorm 1790169
cabozantinib 20 MG Oral Tablet
1 of 4 listed NDCs had Medicaid claims. RxNorm 1790161
cabozantinib 60 MG Oral Tablet
1 of 5 listed NDCs had Medicaid claims. RxNorm 1790173
Other Cabozantinib (thyroid cancer) products: packs and listings not matched to one strength and form
1 of 3 listed NDCs had Medicaid claims.
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 4 of the 16 listed Cabozantinib (thyroid cancer) NDCs had Medicaid claims.
Cabozantinib (thyroid cancer) Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Cabozantinib (thyroid cancer) — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Cabozantinib (thyroid cancer) in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Cabozantinib (thyroid cancer) FDA Approval History
How Cabozantinib (thyroid cancer) went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Cabozantinib (thyroid cancer) Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Cabozantinib recalls since July 2021.
✅No Cabozantinib recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Cabozantinib (thyroid cancer) in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 2
- Strengths
- 5
- Forms in current FDA listings
- 0 of 2
RxCUI 1363268 RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Cabozantinib (thyroid cancer) Supply and Shortage Status
Whether Cabozantinib (thyroid cancer) is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Cabozantinib (thyroid cancer) Brand Names
Cabozantinib (thyroid cancer) has 2 brand names on record: Cometriq and Cabometyx. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Sources for This Cabozantinib (thyroid cancer) Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Exelixis, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →